-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $275

Benzinga·08/11/2026 14:22:23
Listen to the news
Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $260 to $275.